Nouscom AG
Edit

Nouscom AG

http://www.nouscom.com/
Last activity: 11.12.2024
Active
Categories: DevelopmentInformationLEDLifeManagementPersonalPlatformProductTechnologyWebsite
Nouscom is a private oncology company developing next generation immunotherapies. Nouscom’s proprietary technology platform, Exovax, harnesses the full power of immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators.

Nouscom is led by an experienced management team that has worked together for many years in previous successful enterprises, including IRBM/Merck and Okairos (acquired by GSK), and are veterans in the field of genetic vaccines.

Nouscom, which was founded in 2015 and is headquartered in Basel, Switzerland with operations in Rome, Italy, is backed by international life sciences investors: 5AM, Abingworth, LSP (Life Sciences Partners) and Versant Ventures.

For more information on Nouscom, please visit the company’s website at www.nouscom.com
Mentions
36
Location: Switzerland, Basel-City, Basel
Employees: 11-50
Total raised: $135.77M

Investors 5

Funding Rounds 3

DateSeriesAmountInvestors
14.11.2023Series C$73.43M-
06.11.2017Series B$48.77M5AM Ventur...
17.05.2016Series A$13.57M-

Mentions in press and media 36

DateTitleDescription
13.12.2024The Dawn of Drone Dominance: Auterion and Rheinmetall's Game-Changing AllianceIn the world of defense technology, the skies are no longer the limit. They are the battlefield. Auterion, a leader in drone operating systems, has teamed up with Rheinmetall, a titan in defense technology. Together, they are crafting a new...
11.12.2024New leaders with a fresh perspective for several startups Pure Holding, a renowned Swiss cannabis company focusing on research, production, processing & distribution has welcomed Janna Eisenbrandt has joined the leadership team as the new CFO. Janna brings with her a wealth of experience in s...
25.11.2024POWHER Awards für drei Unternehmerinnen Der gemeinnützige Verein «Female Entrepreneurs Basel» hat zum dritten Mal die POWHER Awards in drei Kategorien vergeben. Damit werden Frauen ausgezeichnet, die durch innovatives Handeln und unternehmerisches Engagement Erfolge erzielt habe...
06.11.2024Biotech companies report progress in clinical trials Following the sale of its lead molecule NM26 to Johnson & Johnson for USD 1.25 billion in May, Numab Therapeutics announced the start of a Phase 1 clinical trial evaluating NM32, a next generation tri-specific immuno-oncology therapeut...
27.07.2024The Future of Diagnostics: Roche's Vision Unveiled at ADLM 2024In the bustling heart of Chicago, Roche is setting the stage for the future of laboratory diagnostics. At the 2024 Association for Diagnostics & Laboratory Medicine (ADLM) Clinical Lab Expo, the company is showcasing a suite of innovati...
23.07.2024Erfahrene Expertinnen und Experten verstärken Startup-Management Das EHT-Spin-off Riverkin begrüsst mit Nitin Kumar and Marco Adriano Magno zwei neue Mitgründer. Nitin Kumar hat einen Doktortitel in Computational Biology und war an einigen erfolgreichen Startup-Exits beteiligt. Mit diesen Erfahrungen kö...
26.03.2024Nouscom secures additional funding from Angelini Ventures Based in Basel, Nouscom is a clinical stage immune-oncology company developing off-the-shelf and personalized cancer vaccines based on its proprietary viral vector platform, which has the capacity to encode for large payloads of neoantigen...
21.03.2024Angelini Ventures invests into extended €75.8 million ($82 million) Series C financing round for Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized cancer vacc...-
21.12.2023INDACO VENTURE PARTNERS – NOUSCOM RAISES €67.5 MILLION ($72 MILLION) IN OVERSUBSCRIBED SERIES C FINANCING ROUND
20.12.2023Fierce Biotech Fundraising Tracker '23: Carmot spinoff Kimia raises $55M; Lassen fuels for fibro-inflammatory missionWe've launched a new Fierce Biotech Fundraising Tracker for 2023 to track all the venture capital flowing into the industry. While biotech VC investments in 2022 failed to live up to 2021's banner year, the second half still saw a steady st...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In